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ABSTRACT
Although age-related variations in areal bone mineral density (aBMD) and the prevalence of osteoporosis have been well characterized,
there is a paucity of data on femoral strength in the population. Addressing this issue, we used finite-element analysis of quantitative
computed tomographic scans to assess femoral strength in an age-stratified cohort of 362 women and 317 men, aged 21 to 89 years,
randomly sampled from the population of Rochester, MN, and compared femoral strength with femoral neck aBMD. Percent reductions
over adulthood were much greater for femoral strength (55% in women, 39% in men) than for femoral neck aBMD (26% in women, 21%
in men), an effect that was accentuated in women. Notable declines in strength started in the mid-40s for women and one decade later
for men. At advanced age, most of the strength deficit for women compared with men was a result of this decade-earlier onset of
strength loss for women, this factor being more important than sex-related differences in peak bone strength and annual rates of bone
loss. For both sexes, the prevalence of ‘‘low femoral strength’’ (<3000N) was much higher than the prevalence of osteoporosis (femoral
neck aBMD T-score of  2.5 or less). We conclude that age-related declines in femoral strength are much greater than suggested by age-
relateddeclinesinfemoral neckaBMD.Further,farmoreoftheelderlymaybeathighriskofhipfracture becauseoflowfemoralstrength
thanpreviously assumedbasedonthetraditionalclassification ofosteoporosis.  2010AmericanSociety forBoneandMineralResearch.
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Introduction
O
steoporosis is an underdiagnosed and undertreated
disease, hip fracture being its most severe sequela.
(1)
Low areal bone mineral density (aBMD) at the femoral neck, as
measured by dual-energy X-ray absorptiometry (DXA), is a
powerful determinant of hip fracture
(2) and the recommended
tool for risk assessment.
(3) However, most osteoporotic fractures
occur in individuals who do not have osteoporosis by DXA
criteria.
(4–7) While a number of non-BMD-related factors may
account for this, aBMD is inherently limited in assessing femoral
strength because of its 2D nature and inability to quantify
specific bone compartments or structures.
(8) A more refined
clinical characterization of femoral strength and its dependence
on age therefore may improve our understanding of hip fracture
etiology and lead to better strategies for reducing the burden of
this important clinical problem.
(9)
Finite-element analysis of quantitative computed tomo-
graphic (QCT) scans—termed here biomechanical CT (BCT)—
is the most technologically advanced method currently
available for noninvasive clinical assessment of femoral strength.
This technique has been well validated in cadaver studies
(10–12)
and has been used to provide unique insight into osteop-
orosis therapies.
(13–16) In a recent prospective fracture surveil-
lance study of elderly men,
(17) all men with a BCT-derived
femoral strength value below 2900N suffered a new hip fracture,
suggesting more generally that those with ‘‘low femoral
strength’’ (<3000N) are at high risk of fracture. Further, over
half those who fractured with such low femoral strength were
classified as having osteopenia rather than osteoporosis on the
basis of their DXA-derived aBMD T-score.
The goal of this cross-sectional study was to apply BCT to a
population-based cohort in order to (1) characterize the
variations in femoral strength across age among adult women
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994and men, (2) estimate the prevalence of low femoral strength
(<3000N), and (3) compare these trends with those for femoral
neck aBMD and the prevalence of osteoporosis (femoral neck
aBMD T-score of  2.5 or less).
Methods
Subjects
We analyzed CT data obtained previously from an age-stratified
random sample of Rochester, MN, residents.
(18) This community
ishighlycharacteristicoftheUSwhitepopulation,butblacksand
Asians are underrepresented.
(19) The sample spanned ages from
20 to 97 years and included 375 women and 325 men. Reflecting
the ethnic composition of the community, 98% of the subjects
were white. Thirty-two percent of the men and 29% of the
women were obese, as defined by a weight greater than 30% of
ideal for their height. Ninety-four postmenopausal women were
receiving estrogen therapy, and 6 postmenopausal women and
3 men were receiving bisphosphonate therapy for osteopenia.
Because of the large number of postmenopausal women
receiving estrogen at the time of recruitment, we oversampled
in the 50- to 69-year age range to have adequate numbers of
untreated women for analysis. There was an offsetting under-
sampling of young adult women and men.
As described in detail elsewhere,
(18) single-energy QCT scans
were made at the proximal femur using a multidetector CT
scanner (Light Speed QX-I, GE Medical Systems, Wakesha, WI,
USA) with a slice width of 2.5mm and an in-plane voxel size of
0.74mm. After deleting scans (n¼17) that had image artifacts
that prevented us from performing accurate BCT analysis,
362 women (ages 21 to 97 years) and 317 men (ages 22 to
93 years) remained in the study.
Femoral strength and aBMD measurements
The two main outcomes of our analysis were the BCT-derived
estimate of femoral strength (N) and the quantitative CT-derived
measure of femoral neck aBMD (g/cm
2). To estimate femoral
strength, as described in detail elsewhere,
(15–17) each QCT scan
was converted into a 3D finite-element model of the proximal
femur (Fig. 1) in which the local material properties of cortical
and cancellous bone were assigned from the spatially varying
calibrated Hounsfield units from the CT scan using empirically
derived relations.
(20–22) Each patient-specific finite-element
model then was virtually loaded to failure in simulation of an
unprotected sideways fall with impact on the greater trochanter.
Nonlinear analyses were used in these simulations, the result
being an estimate of the strength of the whole proximal femur.
Laboratory experiments on 76 elderly cadavers loaded in a
sideways fall configuration at high speed have shown a high
correlation (r
2¼0.78) and Y¼X type agreement between such
estimates of femoral strength and direct measures from
biomechanical testing.
(12) To measure femoral neck aBMD, the
QCT scan was projected into the plane of a standard clinical
anteroposterior DXA hip exam. A direct comparison of this CT-
equivalent measure of aBMD with a DXA-measured value was
possible for 100 randomly chosen subjects for whom good-
quality CT and DXA scans were both available at a later date, and
these data confirmed the validity of the CT-derived measure
(r
2¼0.95). The CT-derived measures were scaled linearly to
provide Lunar-equivalent values.
Statistical analysis
Means and 95% confidence intervals (CIs) for femoral strength
and femoral neck aBMD were calculated per decade of age,
except that the two youngest and two oldest groups were
separately pooled because there were not as many 20 to 29 and
90þ year-olds. Linear regression analysis was used on these
mean values to characterize average age-related changes in
femoral strength. In these regressions; we fit only the line to
age > 45 years for women because there was no significant
changebeforetheninthemeanvalues;formen,wefit thelineto
age > 55 years for the same reason. For comparison purposes,
these same age ranges were used to describe the age-related
changes in femoral neck aBMD. The resulting linear regression
equations relating strength (or density) to age then were used
analytically to estimate the average annual percent change in
femoral strength and femoral neck aBMD from these cross-
sectional data. The percent change at each year was calculated
as the change in strength over each single year divided by the
value at the start of that year. To characterize the prevalence of
low femoral strength, we calculated the proportion of the cohort
in each age group having a femoral strength below 3000N. This
cut point was based on our previous analysis—using the same
implementation of the BCT analysis technique as used here—of
incident hip fracture in elderly men
(17); without exception, all
men inthat prospective study who hada femoral strength of less
than 2900N suffered a newhipfracture. Similarly, the prevalence
of femoral neck aBMD T-scores of  2.5 or less was estimated in
each age group. These T-scores were calculated for both sexes
using female young reference values
(23) for Lunar DXA in the
femoral neck region (0.98 0.12g/cm
2).
(24) Comparisons of
femoral neck aBMD with age also were made against equivalent
data from Lunarand Hologic reference values inorder toconfirm
that our cohort was representative of the larger US white
population. The Hologic data were based on the third National
Health and Nutrition Examination Survey (NHANES III).
(25) To
enable comparison of our results with other prevalence studies,
for each outcome the prevalence rate for those aged 50 years
and above was age adjusted to the demographic structure of the
US white population aged 50 years and over in 2000.
Results
Femoral strength and femoral neck aBMD varied in similar ways
with age for each sex, with notable declines starting in the mid-
40s for women and a decade later for men (Fig. 2). Once these
declines started, the linear regression analysis of these cross-
sectional data indicated that there were slightly higher ( 10%)
estimated rates of annual (absolute) loss in femoral strength in
women compared with men (61 versus 55N/year). Similar trends
were observed for femoral neck aBMD, and as expected, the
estimated average rate of loss was slightly higher ( 7%) in
women than in men (5.6 versus 5.2g/cm
2/year). Comparison of
the means and standard deviations of the femoral neck aBMD
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the published reference values from the Lunar and Hologic DXA
manufacturers confirmed the representativeness of our cohort
(Fig. 3).
Despite these apparently similar age trends for femoral
strength and femoral neck aBMD, annual percent reductions in
the most elderly women were over threefold greater for femoral
strength than for femoral aBMD (Fig. 4). The percent reductions
in femoral strength for the oldest group (mean age approxi-
mately 85 years) with respect to the youngest group (mean age
approximately30 years)were55%and39%forwomenandmen,
respectively—about twice the size of the reductions in femoral
neck aBMD (26% and 21%, respectively). Using the linear
regression equations shown in Fig. 2 to calculate annual percent
changes, starting from the first decade at which reductions
occurred, the estimated annual percent reduction in femoral
strength for women ranged from 1.3% at age 45 to 2.8% at
age 85; for femoral neck aBMD, these respective values were
only 0.6% (age 45) and 0.8% (age 85). For men, femoral strength
did not decrease until one decade later; the estimated annual
percent reductions at ages 55 and 85 years were 1.1% and 1.7%,
respectively, for femoral strength, over twice those for femoral
neck aBMD (0.5% and 0.6%).
For both sexes for each age, the prevalence of low femoral
strength (<3000N) was much higher than the prevalence of
osteoporosis (T-score    2.5; Fig. 5). The overall age-adjusted
prevalence for women 50 years of age and older was 43.9% for
low femoral strength compared with 7.2% for osteoporosis; for
men, these values were 18.9% and 1.0%, respectively. The
prevalence of low femoral strength became appreciable (>15%
to20%)atthefifthdecadeforwomenandadecadelaterformen
and then increased with age at similar gradients in both sexes, at
least initially. However, unlike the rather uniform age trends for
mean values of femoral strength, there was an additional
increase in the prevalence of low femoral strength for women
compared with men starting in the seventh decade. By the
Fig. 1. Finite-element models for six subjects: a typical young and old woman and man, as well as the strongest and weakest women in the cohort. The
imagesshowlocalregionsofhigh(red)andlow(blue)strengthbone.Theboneisvirtuallyloadedinatypicalsidewaysfallconfigurationthroughthevirtual
PMMA plates (colored orange) shown at the head and greater trochanter.
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twofold higher for women (89%) than for men (47%), was
substantially greater than the prevalence of osteoporosis (27%
for women, 4% for men).
The prevalence of osteoporosis was similar regardless of
whether the young reference value from the Lunar and the
Hologic manufacturer was used. It was higher when the young
reference value for the Rochester cohort itself was used but still
lower than the prevalence of low femoral strength (Table 1). The
prevalence of low femoral strength remained higher than the
prevalence of osteoporosis (based on the manufacturers’
reference values) even if it was defined as a femoral strength
value less than 2000N.
Discussion
Femoral neck aBMD is correlated with bone strength
(26) and is
the preferred clinical metric for assessing both fracture risk
(3)
Fig. 2. Mean ( 95% CI) values of femoral strength (A) and femoral neck
(FN)aBMD(B)bydecadeofageforRochester,MN,womenandmen.Data
for subjects in the 20- to 39-year age range and over age 80 were pooled
to account for the smaller sample size in those groups (see Table 1 for
sample sizes). Linear regression analysis of these mean data over the
range of the best-fit lines was used to estimate age dependent rates of
loss (for women over age 45 years and men over age 55 years).
Fig. 3. Comparison with published manufacturer/reference values
(24) for
femoral neck (FN) aBMD and FN aBMD as measured in this study for the
Rochester cohort (mean 95% CI). The Hologic data, derived from
NHANES III,
(25) were converted to Lunar-equivalent (L-equiv) values using
the following equation: Lunar¼0.142 þ 1.013   Hologic.
(24) Trends lines
are shown for the Hologic and Lunar data sets. For both sexes, both
manufacturer data sets fall within the 95% CI of the Rochester figures.
Fig. 4. Estimated annualized percent change in femoral strength and
femoral neck aBMD for Rochester, MN, women and men, as calculated
from linear regression analysis of the data shown in Fig. 2.
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(23) However, our results
demonstrate that femoral strength is reduced to a much greater
extentduring adulthood thanwouldbesuggested byreductions
in femoral neck bone density and that this effect is accentuated
in elderly women. We also found that the prevalence of low
femoral strength, as defined in this study (<3000N), was much
greater in this cohort than was the prevalence of osteoporosis.
Our prevalence threshold for femoral strength was based on our
observation that all men in the MrOS prospective fracture
surveillance study who had BCT-derived femoral strength values
of less than 2900N reported a new hip fracture during follow-
up.
(17) Additionally, the hazard ratio for hip fracture per standard
deviation decrease in femoral strength in that study was large
(13.1, 95% CI 3.9–43.5). The MrOS study did not include women,
and no similar studies for women have yet been reported.
Nonetheless, assuming that a femoral strength below 3000N
places any individual at high risk of a hip fracture, our results
suggest that far more of the elderly may be at high risk of hip
fracture because of low femoral strength than previously
assumed based on the traditional femoral neck T-score-based
classification of osteoporosis.
(23) While the incidence of hip
fractures in the elderly at advanced age is much less than the
prevalence of reduced femoral neck strength reported here, this
is so because hip fractures rarely occur without a fall
(27,28);
indeed, a fall generally can be considered as a necessary
condition for a hip fracture.
(14) Despite the important etiologic
role of falls for hip fracture in the elderly, this increased
prevalence of those with low femoral strength compared with
those with low femoral neck aBMD may partially explain why
known reductions in femoral neck aBMD predict only a doubling
of hip fracture risk between the ages of 60 and 80 years instead
of the 13-fold increase actually observed.
(29)
The age-dependent reduction in aBMD as reported from
NHANES III
(25) supports the generality of our study data. In
Fig. 5. Age-specific prevalence of ‘‘low femoral strength’’ (femoral
strength < 3000N) and osteoporosis (femoral neck aBMD T-score   –
2.5) for Rochester, MN, women and men.
Table 1. Prevalence (in Percent) of Osteoporosis (Femoral Neck aBMD T-Score   –2.5) Using Different (Female) Young Reference Values
for the T-Score Calculation (Lunar or Hologic Published Reference Values, Rochester Cohort-Specific Reference Value) and Prevalence of
Low Femoral Strength (Defined by Strength Values less than Either 2000 or 3000N) Among Rochester, MN, Women and Men
Age group
Number of
subjects
Osteoporosis (%)
Low femoral
strength (%)
Lunar
a Hologic
a Rochester
a <2000 <3000
Women
20–39 75 0.0 0.0 1.3 1.3 2.7
40–49 49 0.0 0.0 2.0 0.0 8.2
50–59 74 0.0 0.0 6.8 2.7 21.6
60–69 73 5.5 6.8 16.4 8.2 37.0
70–79 47 10.6 12.8 38.3 17.0 66.0
>80 44 27.3 31.8 70.5 50.0 88.6
Age-adjusted
b 238 7.2 8.6 24.3 13.3 43.9
Men
20–39 75 0.0 0.0 0.0 0.0 0.0
40–49 49 0.0 0.0 0.0 0.0 4.1
50–59 49 0.0 0.0 0.0 0.0 4.1
60–69 47 0.0 0.0 2.1 0.0 17.0
70–79 48 2.1 6.3 20.8 8.3 31.3
>80 49 4.1 6.1 32.7 16.3 46.9
Age-adjusted
b 193 1.0 2.1 9.3 3.9 18.9
aYoung reference values (mean SD) were 0.98 0.12 and 0.85 0.11g/cm
2 for Lunar and Hologic, respectively, and 1.00 0.09g/cm
2 (in Lunar-
equivalent values) for the Rochester cohort. A mean SD value of 0.85 0.11g/cm
2 for femoral neck aBMD on a Hologic densitometer is equivalent to
1.00 0.11g/cm
2 on a Lunar device.
bFor those aged 50 years and older, values were age adjusted to the total population distribution of US whites aged over 50 years in 2000.
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decreased from 0.86g/cm
2 at age 25 years to 0.57g/cm
2 at age
80 years. This rate of decrease ( 0.55% per year) is entirely
consistent with our results. However, overall prevalence values
depend on the cutoff value used to define osteoporosis,
(30,31)
and as shown in Table 1, our results were sensitive to this
parameter. This sensitivity was mainly due to the slightly smaller
standard deviation in aBMD for the Rochester young reference
group than for the manufacturer cohorts (Table 1), presumably
owing to the more uniform nature of the Rochester cohort
compared with that used in NHANES III. It also may have been
influenced by having a single experienced technician make all
theCTmeasurementsintheRochestercohort.Moreover,suchCT
measurements enable more standardized positioning of the
femoral neck during calculation of aBMD values and thus
introduce fewer random measurement errors from misalign-
ment. We chose to follow clinical guidelines and thus defined
T-scoresusingamanufacturer-specifiedvalueforayoungfemale
reference for both sexes.
(23)
Likewise, the cut point chosen to define ‘‘low femoral
strength’’ was based on our observations among elderly men
in MrOS, in which all men with a femoral strength of less than
2900N fractured their hip during the mean 5.6-year surveillance
period.
(17) It is possible that factors associated with the CT
scanning protocol may alter this value in other study
populations, or the value may be different in women. However,
BCT analysis in two drug studies on osteoporotic postmeno-
pausal women both reported average values of femoral
strength at baseline of about 2500N.
(15,16) These two studies
used the same techniques as employed here for the finite-
elementmodelingbutemployeddifferentinstrumentsandscan-
acquisition protocols for the CT scanning. Since the entry criteria
in these drug studies were designed to include only women at
high risk of fracture using well-accepted clinical criteria, these
data suggest that our assumed cut point for defining ‘‘low
femoral strength’’ is relevant clinically in terms of identifying
those at a high risk of fracture. Further, using a much lower cut
point of 2000N to define low femoral strength also resulted in a
higher prevalence than for the traditional clinical definition of
osteoporosis using manufacturer young reference values for
aBMD.
One notable finding was the greater percentage age-related
reduction in the femoral strength of elderly women compared
with the reduction in aBMD. Ideally, any such changes should
be measured using a longitudinal study design because it is
possible that historical influences of diet or activity level
could produce an age dependence in a cross-sectional analysis
that is not indicative of present-day rates of change.
(32) However,
the age- and sex-dependent estimated variations of femoral
strength reported here from cross-sectional data are consistent
with rates of change reported from 6-year longitudinal
measurements of volumetric trabecular density at the lumbar
spine, as measured by QCT for this cohort.
(33) Further, the same
BCT technique as used in this study was applied recently to a
longitudinal observational study of ibandronate versus placebo
(both groups receiving calcium and vitamin D) in osteoporotic
postmenopausal women.
(16) In that 12-month study, the aver-
age loss of femoral strength for the placebo group (data for
35 subjects, mean age approximately 64 years) was just under
4% (95% CI  1.5–6.2). The average value of femoral strength for
that osteoporotic placebo group at baseline was about 2500N.
Such a value is typical of 78-year-old women in the community-
sampled Rochester cohort, and our regression analysis indicated
that the average annual percent loss of femoral strength for a
78-year-old was about 2.4%. This is statistically consistent with
the finding from the ibandronate study. Although changes in
femoral neck aBMD for the placebo group were not reported in
that study, other much larger studies have reported annual
reductions in total hip or femoral neck aBMD in placebo groups,
in trials on postmenopausal women, of well under 1.0%.
(34,35)
Thus, biomechanically, there appear to be far greater annual
reductions in femoral strength among those with already low
femoral strength than previously suspected based on measured
changes in DXA-derived aBMD.
The greater age-related decrease observed for femoral
strength than for femoral neck aBMD indicates that the age
dependence of aBMD underestimates the full effects of aging on
femoral strength. There are a number of possible reasons
why this is the case. First, in our computer models, based on
observations from cadaver studies,
(36) there is a nonlinear
relation between changes in trabecular bone density and
changes in trabecular bone strength such that changes in
strength exceed changes in density. Second, as reported in an
earlier cross-sectional analysis of this cohort,
(18) changes in trab-
ecular volumetric bone density over adulthood are almost
twice as large as changes in cortical volumetric density. These
differential changes in trabecular and cortical volumetric
density together can result in changes in femoral neck aBMD
that underestimate the true changes in volumetric density of
the weakest bone within the femur, namely, the trabecular bone.
A third reason for the greater change in strength compared
with aBMD is that DXA measures average bone density within
a region of interest, including the thickness of the bone. By
its 2D nature, DXA is relatively insensitive to focal bone loss,
particularly in the femoral neck and intertrochanteric regions,
where clinical fractures occur more frequently.
(37) By contrast,
such local weaknesses would substantially influence the BCT-
derived measurement of bone strength because the finite-
element model will fail in the locally weakest regions. As a
result, the BCT approach can detect individuals at the very low
end of the distribution of femoral strength who appear to
have more normal values of femoral neck aBMD. This, and
possible age-related differences in the relative loss of cortical
and trabecular bone,
(18,38) may explain why many osteopenic
menintheMrOSfracturesurveillancestudywhohadanewhip
fracture also had low femoral strength (<3000N). Such
averaging effects on bone density also have been noted in
assessments of drug therapies. For example, in a recent BCT
study of the biomechanical effects of parathyroid hormone
after 1year of treatment,
(15) DXA-measured total hip aBMD did
not change, whereas BCT-derived femoral strength increased.
Thisoccurred becausetrabecular density increased but cortical
density decreased; the differential changes in the cortical and
trabecular compartments had a canceling-out effect for total
hip aBMD but a biomechanically net positive effect for femoral
strength.
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related differences in peak bone mass and in the subsequent
annual rate of loss of femoral strength appear to be less
important biomechanically than the earlier onset of strength loss
that occurs among women. At age 85 years, we found that
femoral strength, on average, was about 1000N less for women
than for men. The rate of loss of femoral strength, once it starts
forboth sexes,wasabout 6N/year higherinwomen thaninmen;
between the ages of 55 and 85 years, this corresponds to an
accumulated strength deficit of 180N. Thus, only about 18% of
the sex-related strength deficit at age 85 resulted from sex-
related differences in the rate of bone loss (once it starts).
However, we also found that the annual loss of femoral strength
in women ( 60N/year) began about one decade earlier than in
men. This decade-earlier onset of strength loss for women is
important because it corresponds to an accumulated strength
deficit of 600N over the decade relative to men, which
represents about 60% of the sex-related strength difference at
age 85 years. The remaining 22% of this strength deficit at age
85 was due to differences in peak bone mass and any minor loss
of strength before middle age. It follows, then, that women’s
bones are much weaker than men’s bones in old age mainly
because women begin to lose strength earlier—sex-related
differences in peak bone mass and the rate of bone loss, though
important, are much less so than this early-onset effect.
This study has a number of strengths and limitations. The
primary strengths include the age-stratified nature of the study
cohort, which was randomly sampled from the local population,
and the use of the sophisticated BCT analysis technique, which
provides a noninvasive estimate of femoral strength. While the
data in Fig. 3 suggest that our cohort is representative of the
larger US population, it is not clear how these trends extend to
other populations in this country or elsewhere. An evaluation of
nonwhite subjects using this approach would be of particular
interest.
(39) Moreover, our study is limited by the relatively small
sizeofourcohort( 50subjectspersexperdecadeofage).Italso
remains to be seen from other fracture surveillance studies if our
assumed prevalence threshold value of 3000N for ‘‘low femoral
strength’’isasindicativeofahighriskofhipfractureinwomenas
it is in men. We note also that our measures of femoral strength
are estimates and, though well validated in cadaver studies,
(10,11)
are based on models that do not include such patient-
specific submillimeter characteristics as trabecular microarchi-
tecture, collagen cross-linking, or alterations in the remodeling
space.
(8,40) While it is not clear if such characteristics play an
appreciable role in clinical fracture risk assessment, the BCT
measure of femoral strength used in this study has been shown
tobehighlypredictiveofincidenthipfracturesinelderlymen.
(17)
Finally, although assessment of aBMD at the femoral neck is the
preferred region for definition of osteoporosis,
(41) we did not
include total-hip, trochanteric, or spine aBMD measurements in
this study when defining osteoporosis, nor did we address how
inclusion of various other clinical factors such as age and history
of previous fracture would alter the prevalence of those defined
at high risk of hip fracture.
(42) Including such parameters into the
analysis represents an interesting follow-up study.
Our results may have clinical implications because they
suggest that osteoporosis is underdiagnosed not only because
an insufficient number of individuals are screened but also
because DXA misses identifying many of those who are at high
risk of fracture because of low femoral strength. Given the high
prevalence of women with low femoral strength at advanced
age, the paradigm of treating only those identified by DXA as
being at high risk may be inherently flawed because it is more
reactive than preventative. It may be that the optimal time to
treat women should be sooner rather than later so as to prevent
femoral strength from reaching such low levels in so many
women. Since the rate of strength loss is relatively uniform with
age once it starts, such early treatment might occur in the late
40s, 50s, or early 60s and potentially be equally effective for a
given time course of treatment. Delaying the onset of bone loss
in women should have even greater clinical impact because our
calculations indicate that this early onset is the primary reason
whywomenhavesuchlowbonestrengthcomparedwithmenat
advanced age. While justifying any such strategies would require
further study, the data presented here suggest that clinically
relevant levels of low femoral strength are much more common
in the general population than indicated by the prevalence of
osteoporosis as currently defined by assessment of aBMD at the
femoral neck.
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